Melatonin for Sleep and Jet Lag: What the Evidence Really Shows

Institutional reviews describe melatonin as a hormone involved in darkness signaling and sleep timing. NCCIH summarizes a 2022 review of 12 studies with 2,666 participants showing improvement in sleep-onset latency and some daytime functioning measures, but little evidence for major gains in overall sleep quality or reduced time awake during the night. NCCIH — Sleep Disorders In Depth; Mayo Clinic — Melatonin.

In 8 of 10 trials, melatonin taken close to local bedtime at the destination reduced jet lag after flights crossing five or more time zones. Doses from 0.5 mg to 5 mg appeared similarly effective overall, while doses above 5 mg did not appear more effective. Cochrane Review — Melatonin for Jet Lag.

AASM practice parameters support timed melatonin for jet lag disorder, delayed sleep phase disorder, and free-running disorder in unsighted persons. In delayed sleep phase disorder, a meta-analysis found advances of about 1.18 hours in endogenous melatonin onset and 0.67 hours in clock-time sleep onset, showing more meaningful shifts than those seen in broad insomnia studies. AASM — Circadian Rhythm Practice Parameters; PubMed — Delayed Sleep Phase Disorder Meta-analysis.

In children and adolescents with autism spectrum disorder or Smith-Magenis syndrome and insomnia, prolonged-release melatonin 2 mg to 5 mg improved sleep duration and sleep onset over 13 weeks. The evidence supports a narrow, supervised clinical use rather than broad self-treatment for all children. PubMed — Pediatric Prolonged-Release Melatonin Trial; EMA — Slenyto.

Short-term adult tolerability appears reasonably good, including in some higher-dose studies, but public health surveillance also shows a major rise in pediatric ingestions. Analytical studies found large variability in melatonin content across supplements, including products with 0 percent to 667 percent of labeled content and some containing serotonin. PubMed — High-Dose Melatonin Safety Review; CDC — Pediatric Melatonin Ingestions Report; PubMed — Melatonin Content Variability Study; PubMed — Child-Targeted Supplement Analysis.

The evidence reviewed does not support that broad claim. In adults with chronic insomnia, pooled studies usually show small average benefits, mainly in how quickly some people fall asleep, and the AASM guideline suggests clinicians not use melatonin routinely for adult sleep-onset or sleep-maintenance insomnia. PubMed — Melatonin Meta-analysis; PubMed — AASM Chronic Insomnia Guideline.

The evidence does not support simple dose escalation as a reliable strategy. In jet lag trials, doses above 5 mg did not show added benefit, and newer dose-response work suggests that timing may matter as much as or more than dose, which fits melatonin's role as a clock-setting signal rather than a stronger-is-better sedative. Cochrane Review — Melatonin for Jet Lag; PubMed — 2024 Dose-Response Meta-analysis.

Because melatonin is natural and sold over the counter, many people assume quality and regulation are not major concerns. In reality, U.S. supplements are not preapproved by FDA for effectiveness, analytical surveys have found large discrepancies between labeled and measured melatonin content, and some products have contained serotonin. Broad anti-aging, immune, cancer, and general wellness claims were also not established in the evidence reviewed here. FDA — Melatonin Regulatory Warning Letter; PubMed — Melatonin Content Variability Study; PubMed — Child-Targeted Supplement Analysis; PubMed — Melatonin in Foods and Plants Review.

Melatonin is produced naturally by the body, mainly in relation to darkness, and acts as a signal that helps coordinate sleep timing and circadian rhythm. That makes supplemental melatonin better described as a hormone-based chronobiology tool than as a standard nutrient. Small amounts do occur in plants and foods, and dietary melatonin may be absorbed, but the evidence reviewed here does not support calling melatonin an essential nutrient with a required daily intake or a recognized deficiency disease. The modern supplement story is therefore mainly about manufactured melatonin used to influence sleep timing, not about replacing a missing nutrient. Mayo Clinic — Melatonin; PubMed — Melatonin in Foods and Plants Review.

The evidence base also gives melatonin a more modern identity than many consumers assume. Unlike many herbal sleep aids, it does not have a central traditional medicine framework in the reviewed material. Its current use follows from laboratory and clinical sleep research rather than from Ayurveda, traditional Chinese medicine, or folk-medicine traditions. That distinction matters because people often group melatonin with “natural” remedies when its main rationale is modern sleep science and circadian biology. NCCIH — Sleep Disorders In Depth.

The clearest pattern across reviews and guidelines is that melatonin performs best when sleep problems reflect a mistimed body clock. The Cochrane review found that melatonin reduced jet lag in most trials involving travel across five or more time zones when taken near local bedtime at the destination. AASM practice parameters also support timed melatonin administration for jet lag disorder, delayed sleep phase disorder, and free-running disorder in unsighted persons. This suggests melatonin is usually more effective when it is used to shift or anchor sleep timing than when it is used as a general sedative for every type of sleeplessness. Cochrane Review — Melatonin for Jet Lag; AASM — Circadian Rhythm Practice Parameters.

Delayed sleep-wake phase disorder is one of the best examples. In this condition, the body clock runs late, so people do not feel sleepy until very late and struggle to wake at conventional times. A meta-analysis reported advances of about 1.18 hours in endogenous melatonin onset and about 0.67 hours in clock-time sleep onset. Studied regimens in guideline material ranged from 0.3 mg to 5 mg, often given 1.5 to 6 hours before habitual bedtime rather than right at bedtime. These are more meaningful shifts than the small average gains seen in general insomnia trials because they address the timing problem directly. PubMed — Delayed Sleep Phase Disorder Meta-analysis; AASM — Circadian Rhythm Practice Parameters.

The public often expects melatonin to behave like a strong sleep medicine, but pooled evidence suggests a much smaller effect in broad adult insomnia. One meta-analysis found about a 4-minute reduction in sleep-onset latency, a 2.2 percent increase in sleep efficiency, and roughly 12.8 minutes of added total sleep time. NCCIH's summary of more recent evidence similarly suggests improvement in falling asleep and some daytime symptoms, but not consistent improvement in sleep quality or waking during the night. This helps explain why some users report benefit while many others do not experience a major change. PubMed — Melatonin Meta-analysis; NCCIH — Sleep Disorders In Depth.

Guidelines add an important layer because they evaluate not just whether an effect exists, but whether it is large and reliable enough to recommend in practice. The AASM adult chronic insomnia guideline suggests that clinicians not use melatonin for routine treatment of sleep-onset or sleep-maintenance insomnia in adults. That does not mean melatonin never helps, but it does mean the overall balance of effect size, consistency, and clinical usefulness was not strong enough for routine pharmacologic recommendation. PubMed — AASM Chronic Insomnia Guideline.

Melatonin products are sold in immediate-release and prolonged-release forms, and these are not interchangeable in practice. Immediate-release products may be more relevant when the goal is sleep initiation or circadian timing, while prolonged-release products may better mimic sustained nighttime exposure in selected settings. Human oral bioavailability varies widely, roughly from 9 percent to 33 percent across studies, which means the same labeled dose can produce very different blood levels in different people. This variability helps explain why a one-size-fits-all approach often fails. PubMed — Melatonin Pharmacokinetics Review; EMA — Slenyto.

A 2024 dose-response meta-analysis adds to that picture by suggesting that taking melatonin around 3 hours before desired bedtime and at around 4 mg may optimize sleep-promoting effects better than the very common consumer habit of taking 2 mg about 30 minutes before bed. This finding fits melatonin's mechanism as a timing cue, although the review does not establish a universal official dosing standard. In practice, some dissatisfaction with melatonin may reflect poor timing rather than complete lack of effect. PubMed — 2024 Dose-Response Meta-analysis.

Supplement quality is a major practical caveat, especially in the U.S. market. Analytical research on commercial products shows that melatonin content can differ dramatically from the label. One study of 110 child-targeted U.S. melatonin supplements found melatonin ranging from 0 percent to 667 percent of labeled content, and another documented significant variability plus serotonin in some products. When the stated dose is unreliable, both effectiveness and safety become harder to predict. PubMed — Child-Targeted Supplement Analysis; PubMed — Melatonin Content Variability Study.

Use is also rising, which increases the public health stakes. NIH reporting based on NHANES data found that adult melatonin use rose from 0.4 percent in 1999-2000 to 2.1 percent in 2017-2018, while poison center data showed a major rise in pediatric ingestions, with increasing hospitalizations and rare severe outcomes. Short-term adult safety is reasonably reassuring, but long-term nightly use, pregnancy, and breastfeeding remain evidence-poor areas. These observations support a focused, supervised view of melatonin rather than a blanket assumption that over-the-counter availability proves broad safety or benefit. NIH — Use of Melatonin Supplements Rising Among Adults; CDC — Pediatric Melatonin Ingestions Report; PubMed — High-Dose Melatonin Safety Review; NCBI Bookshelf — Melatonin and Pregnancy/Breastfeeding.